ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Phase 3

Completed

Conditions: Hepatitis C Genotype 1a
Chronic Hepatitis C
Hepatitis C (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir
Drug: ribavirin

First Posted Date: 2015-06-19

Last Posted Date: 2017-10-03

Lead Sponsor: AbbVie

Target Recruit Count: 25

Registration Number: NCT02476617

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Terminated

Conditions: Ovarian Cancer
Ovarian Neoplasm

Interventions: Drug: Paclitaxel
Drug: Veliparib
Drug: Carboplatin
Other: Placebo to Veliparib

First Posted Date: 2015-06-12

Last Posted Date: 2024-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 1140

Registration Number: NCT02470585

Locations: 🇺🇸
Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, United States
🇺🇸
The Ohio State University - Columbus /ID# 138053, Columbus, Ohio, United States
🇺🇸
Fox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, United States

and more 207 locations

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: ABBV-838
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2015-06-04

Last Posted Date: 2018-09-13

Lead Sponsor: AbbVie

Target Recruit Count: 74

Registration Number: NCT02462525

Locations: 🇺🇸
Washington University School of Medicine /ID# 135708, Saint Louis, Missouri, United States
🇺🇸
Mount Sinai Medical Center /ID# 133569, New York, New York, United States
🇺🇸
The University of Chicago Medical Center /ID# 139403, Chicago, Illinois, United States

and more 16 locations

An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)

Completed

Conditions: Crohn's Disease
Rheumatoid Arthritis
Psoriasis

First Posted Date: 2015-05-22

Last Posted Date: 2019-06-19

Lead Sponsor: AbbVie

Target Recruit Count: 168

Registration Number: NCT02451839

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Phase 2

Completed

Conditions: Chronic Hepatitis C
Hepatitis C Virus
HCV
Direct-Acting Antiviral Agent (DAA)-Experienced

Interventions: Drug: ABT-493, ABT-530
Drug: ABT-493/ABT-530
Drug: ribavirin (RBV)

First Posted Date: 2015-05-18

Last Posted Date: 2017-09-15

Lead Sponsor: AbbVie

Target Recruit Count: 141

Registration Number: NCT02446717

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ribavirin

First Posted Date: 2015-05-13

Last Posted Date: 2017-08-01

Lead Sponsor: AbbVie

Target Recruit Count: 222

Registration Number: NCT02442271

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

Phase 3

Completed

Conditions: Hepatitis C Virus
Chronic Hepatitis C
Cirrhosis

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: Ribavirin

First Posted Date: 2015-05-13

Last Posted Date: 2017-10-16

Lead Sponsor: AbbVie

Target Recruit Count: 99

Registration Number: NCT02442284

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: placebo
Drug: risankizumab

First Posted Date: 2015-05-13

Last Posted Date: 2019-04-10

Lead Sponsor: AbbVie

Target Recruit Count: 214

Registration Number: NCT02443298

Locations: 🇬🇧
Wishaw General Hospital, Wishaw, United Kingdom
🇳🇱
HagaZiekenhuis, Den Haag, Netherlands
🇵🇱
Univ. Hospital in Krakow,Pulmonology Clinical Dept, Krakow, Poland

and more 61 locations

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: ABT-493
Drug: ABT-530

First Posted Date: 2015-05-13

Last Posted Date: 2016-02-22

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02442258

Locations: 🇺🇸
Site Reference ID/Investigator# 132890, Miami, Florida, United States
🇳🇿
Site Reference ID/Investigator# 137332, Grafton, Auckland, New Zealand
🇺🇸
Site Reference ID/Investigator# 132889, Orlando, Florida, United States

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: ABT-493
Drug: ABT-530

First Posted Date: 2015-05-12

Last Posted Date: 2020-09-21

Lead Sponsor: AbbVie

Target Recruit Count: 384

Registration Number: NCT02441283

Locations: 🇨🇦
Toronto Liver Centre /ID# 155401, Toronto, Ontario, Canada
🇺🇸
Digestive Health Specialists of the Southeast /ID# 136725, Dothan, Alabama, United States
🇺🇸
Southern California Res. Ctr. /ID# 141799, Coronado, California, United States

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy